The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Official Title: A Phase II Study of BMS-354825 in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
Study ID: NCT00101595
Brief Summary: The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia with primary or acquired resistance to imatinib mesylate.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Local Institution, Birmingham, Alabama, United States
Local Institution, Anaheim, California, United States
Local Institution, Los Angeles, California, United States
Local Institution, Stanford, California, United States
Local Institution, Vallejo, California, United States
Local Institution, Jacksonville, Florida, United States
Local Institution, Tampa, Florida, United States
Local Institution, Atlanta, Georgia, United States
Local Institution, Chicago, Illinois, United States
Local Institution, Kansas City, Kansas, United States
Local Institution, Boston, Massachusetts, United States
Local Institution, St. Louis, Missouri, United States
Local Institution, Hackensack, New Jersey, United States
Local Institution, New York, New York, United States
Local Institution, Portland, Oregon, United States
Local Institution, Pittsburgh, Pennsylvania, United States
Local Institution, Nashville, Tennessee, United States
Local Institution, Houston, Texas, United States
Local Institution, Buenos Aires, , Argentina
Local Institution, Cordoba, , Argentina
Local Institution, St. Leonards, New South Wales, Australia
Local Institution, Wien, , Austria
Local Institution, B-Leuven, , Belgium
Local Institution, Edegem, , Belgium
Local Institution, Yvoir, , Belgium
Local Institution, Campinas, , Brazil
Local Institution, Sao Paulo, , Brazil
Local Institution, Toronto, Ontario, Canada
Local Institution, Montreal, Quebec, Canada
Local Institution, Aarhus, , Denmark
Local Institution, Helsinki, , Finland
Local Institution, Lille, , France
Local Institution, Lyon Cedex 03, , France
Local Institution, Nantes, , France
Local Institution, Paris, , France
Local Institution, Pessac, , France
Local Institution, Poitiers Cedex, , France
Local Institution, Strasbourg Cedex, , France
Local Institution, Frankfurt/Main, , Germany
Local Institution, Hamburg, , Germany
Local Institution, Mainz, , Germany
Local Institution, Mannheim, , Germany
Local Institution, Ramat-Gan, , Israel
Local Institution, Bologna, , Italy
Local Institution, Orbassano, , Italy
Local Institution, Roma, , Italy
Local Institution, Kyunggi-Do, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Nijmegen, , Netherlands
Local Institution, Rotterdam, , Netherlands
Local Institution, Trondheim, , Norway
Local Institution, Lima, , Peru
Local Institution, Gothenburg, , Sweden
Local Institution, Lund, , Sweden
Local Institution, Stockholm, , Sweden
Local Institution, Umea, , Sweden
Local Institution, Uppsala, , Sweden
Local Institution, Basel, , Switzerland
Local Institution, Glasgow, Central, United Kingdom
Local Institution, London, Greater London, United Kingdom
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR